[mft_]

Yes, with nuances.

The recently-read-out trial is in the 'second line' - meaning patients will have received one 'line' of treatment before this - typically chemotherapy +/- surgery. The chemotherapy regimes used for pancreatic cancer can be pretty brutal, and patients can usually tolerate one, max two lines overall. As such, this trial administering only daraxonrasib monotherapy made sense.

The first line trial of daraxonrasib is already underway, and includes both darax monotherapy and darax + chemo arms. (They are combining with a slightly less brutal chemotherapy called GnP, with an eye to the overall side effect burden considering the non-trial side effects that darax also brings.)

It'll be very interesting to see the outcome of this trial; there are some examples elsewhere in oncology where a treatment is recommended by guidelines without chemotherapy over a combination with chemotherapy, as the small survival benefit the addition of chemotherapy brings is seen as outweighed by the additional toxicity.